Multi-Center, Placebo-Controlled, Dose-Ranging Phase 2 Electrophysiological Study of Intranasal Administration of MSP-2017 for the Conversion of Induced Paroxysmal Supraventricular Tachycardia to Sinus Rhythm

Trial Profile

Multi-Center, Placebo-Controlled, Dose-Ranging Phase 2 Electrophysiological Study of Intranasal Administration of MSP-2017 for the Conversion of Induced Paroxysmal Supraventricular Tachycardia to Sinus Rhythm

Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs Etripamil (Primary)
  • Indications Paroxysmal supraventricular tachycardia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms NODE-1
  • Sponsors Milestone Pharmaceuticals
  • Most Recent Events

    • 11 May 2017 Primary endpoint (The percentage of subjects successfully converted to sinus rhythm within 15 minutes of study drug administration) has been met, according to a Milestone Pharmaceuticals media release.
    • 11 May 2017 According to a Milestone Pharmaceuticals media release, results from this trial were presented at the Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions.
    • 11 May 2017 Results published in a MIlestone Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top